Pharma: Page 14
-
Stock via Getty Images
Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS
Ahead of more guidance from the FDA on diversity in clinical trials, Takeda is aiming to beat industry standards.
By Amy Baxter • March 27, 2024 -
Permission granted by Alnylam
Alnylam turns to genealogy to find rare disease patients through family trees
A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.
By Michael Gibney • March 26, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
iStock via Getty Images
Who’s getting left behind in the weight loss bonanza?
As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.
By Kelly Bilodeau • March 25, 2024 -
Permission granted by Boehringer Ingelheim
Q&AWhy a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
By Alexandra Pecci • March 25, 2024 -
Permission granted by Gates MRI
ProfileThe pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle
After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.
By Alexandra Pecci • March 22, 2024 -
Permission granted by Wyss Institute
Q&AAn ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
By Michael Gibney • March 21, 2024 -
Courtesy of Madrigal
With historic MASH approval, Madrigal preps for launch and a public offering
After snagging the first approval for MASH, Madrigal Pharmaceuticals’ drug is primed to become a blockbuster.
By Amy Baxter • March 20, 2024 -
Getty Images via Getty Images
As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help
A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.
By Michael Gibney • March 19, 2024 -
Stock via Getty Images
Q&A // Biotech SpotlightGSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
By Alexandra Pecci • March 19, 2024 -
Kevin Dietsch via Getty Images
5 Big Pharma CEOs who saw major pay bumps in 2023
Pharma’s recent wins have led to pay windfalls for several company leaders.
By Amy Baxter • March 18, 2024 -
Permission granted by Aily Labs
Ex-Novartis exec sets out to create ‘Apple of AI’
Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.
By Kelly Bilodeau • March 18, 2024 -
Stock via Getty Images
After Amylyx drug failure, what’s next for ALS?
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
By Meagan Parrish • March 15, 2024 -
Alex Wong/Getty Images via Getty Images
Q&AFormer U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
By Michael Gibney • March 14, 2024 -
Stock via Getty Images
The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs
Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.
By Michael Gibney • March 12, 2024 -
Stock via Getty Images
As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients
As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.
By Alexandra Pecci • March 12, 2024 -
Scott Olson via Getty Images
COVID vaccine giants Moderna and Pfizer employ divergent tactics for the next chapter
With COVID-19 vaccine sales dying down, Pfizer and Moderna turn to growth in different ways to cement their status as mRNA leaders.
By Amy Baxter • March 11, 2024 -
Stock via Getty Images
Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D
The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.
By Kelly Bilodeau • March 11, 2024 -
Adobe Stock / LuneVA/peopleimages.com
Sponsored by MMITWhy pharma should prioritize the patient journey: A survivor’s story
One rare disease survivor’s diagnosis experience highlights the need for pharma companies to better understand the patient journey.
By Carolyn Zele, Solution Consulting Advisor, MMIT • March 11, 2024 -
Permission granted by Tarsus Pharmaceuticals
Q&AInto the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
By Meagan Parrish • March 8, 2024 -
Permission granted by Amylyx Pharmaceuticals
Amylyx ALS drug fails crucial study, putting company’s future in doubt
The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.
By Jacob Bell • Updated March 8, 2024 -
Mario Tama via Getty Images
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.
By Michael Gibney • March 7, 2024 -
Kevin Dietsch via Getty Images
Could pharma’s legal attack on the IRA succeed in killing price negotiations?
An all-out blitz across U.S. courts is bolstering pharma’s goal to overturn Medicare drug price negotiations.
By Amy Baxter • March 6, 2024 -
Stock via Getty Images
Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches
Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.
By Kelly Bilodeau • March 6, 2024 -
Permission granted by Natalie Ferguson/American Gene Technologies
ProfileHIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure
From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.
By Michael Gibney • March 5, 2024 -
Anna Moneymaker via Getty Images
After ‘tragic’ bacterial outbreak, lawmakers press FDA to step up foreign inspections
Impatience to fix long-held challenges to overseas drug facility inspections is growing on Capitol Hill.
By Amy Baxter • March 1, 2024
Previous
